DAY 1 – Wednesday, November 16, 6-9 p.m.
POSTER SESSION AND RECEPTION
Welcome: Todd Gilman, Chair, NETRF Board of Directors

DAY 2 – Thursday, November 17, 9 a.m.-5 p.m.
Welcome: Elyse Gellerman, CEO, NETRF
Overview: John Kanki, PhD, NETRF Director of Research

SESSION 1: NET MODELS
Moderators: Dawn Quelle, PhD, University of Iowa
           Justin Annes, MD, PhD, Stanford University

• Patient Derived Tumor Organoid Models Reveal Druggable Growth Dependencies in Neuroendocrine Cancer
  Talya Dayton, PhD, Barcelona European Molecular Biology Laboratory

• Mechanisms, Models, and Treatments for Neuroendocrine Tumors
  James Bibb, PhD, University of Alabama at Birmingham

• Improving SBNET Therapy by Targeting Serotonin Metabolism
  Po Hien Ear, PhD, The University of Iowa

• Validation of Pheochromocytoma Organoid Models
  Patricia Dahia, MD, PhD and Alice Soragni, PhD, University of Texas Health Science Center at San Antonio/
  University of California, Los Angeles

Discussion

SESSION 2: GENETICS
Moderators: Ramesh Shivdasani, MD, PhD, Dana-Farber Cancer Institute
           Carl Gay, MD, PhD, University of Texas, MD Anderson Cancer Center

• Immunophenotypic and Molecular Characterization of Pancreatic Neuroendocrine Tumors Producing Serotonin
  Jérôme Cros, MD, PhD, University of Paris

• Genomic and Epigenomic Analyses of Multifocal Ileal Neuroendocrine Tumors
  Netta Makinen, PhD and Matt Meyerson, MD, PhD, Dana-Farber Cancer Institute

• Characterising Aggressive Pulmonary Carcinoids Through Integrative Omics Analysis Within the lungNENomics Project
  Matthieu Foll, PhD and Lynette Fernandez-Cuesta, PhD, International Agency for Research on Cancer

• Regulatory Heterogeneity of Neuroendocrine Tumors
  Yotam Drier, PhD, Hebrew University of Jerusalem

• Developmental Lineages and Mediators of Metastasis in PNETs at Single-Cell Resolution
  William Hwang, MD, PhD and Carina Shiau, BA, Massachusetts General Hospital

Discussion
SESSION 3: TUMOR MICROENVIRONMENT AND IMMUNOLOGY

Moderators: Dan Halperin, MD, University of Texas, MD Anderson Cancer Center
Matt Kulke, MD, Boston Medical Center

• Vascular Regulation of Liver Metastasis in Pancreatic Neuroendocrine Tumors
  Minah Kim, PhD, Columbia University Medical Center

• Ex vivo Expansion of TILs from panNET Liver Metastasis: In Search of Novel Adoptive Transfer Strategies for the Treatment of NETs
  Mauro Cives, MD, University of Bari Aldo Moro (Università degli Studi di Bari Aldo Moro)

• The 3rd Generation of CDH17CAR T Cells Eliminate NETs and GI-solid Tumors via Enhancing Multiple T Cell Signaling Pathways
  Xianxin Hua, MD, PhD, The Trustees of the University of Pennsylvania

• CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors
  Dawn Quelle, PhD, The University of Iowa

• The Role of the B7x Signaling Pathway in the Development and Progression of Neuroendocrine Tumors
  Ziqiang Yuan, MD and Steve Libutti, MD, Rutgers, The State University of New Jersey-RBHS-CINJ

Discussion

SPECIAL SESSION: NET MODELS CONSORTIUM

Moderators: Dawn Quelle, PhD, University of Iowa
Justin Annes, MD, PhD, Stanford University

• Short Presentations: NET Cell Lines, Organoids and Mice
  - Dawn Quelle, PhD, University of Iowa
  - Talya Dalton, PhD, Barcelona European Molecular Biology Laboratory
  - Maite Calucho, PhD, Alice Soragni, PhD, Patricia Dahia, MD, PhD, University of California, Los Angeles, University of Texas Health Science Center at San Antonio
  - Justin Annes, MD, PhD, Stanford University

Discussion
DAY 3 – Friday, November 18, 9 a.m.-1:30 p.m.

SESSION 4: TUMOR BIOLOGY AND RARE NETS

Moderators: Chrissie Thirlwell, MBBS, PhD, University of Exeter Medical School
James Bibb, PhD, University of Alabama at Birmingham

• Insights into Intestinal NETs from an In Vitro Model of Human EEC Differentiation
  Pratik Singh, PhD and Ramesh Shivdasani, MD, PhD, Dana-Farber Cancer Institute

• Human and Murine Single-nucleus RNA-seq (snRNA-seq) Reveals Potential Mechanisms of
  TMEM127-mediated Susceptibility to Pheochromocytomas
  Qianjin Guo, PhD and Patricia Dahia, MD, PhD, University of Texas Health Science Center at San Antonio
  (UT Health San Antonio)

• Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
  Martyn Caplin, DM, FRCP, Maria C. Martins, Harry Hodgetts, UCL Institute for Liver and Digestive Health

• The Role of CCL2 and IL-8 in the Microenvironment of Pituitary Neuroendocrine Tumors
  Pedro Marques, MD, PhD, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE

• Defining Distinct Molecular Subtypes of High-grade Neuroendocrine Carcinomas to Predict
  Therapeutic Vulnerabilities
  Allison Stewart, PhD and Carl Gay, MD, PhD, University of Texas M.D. Anderson Cancer Center

• All-Trans Retinoic Acid Radiosensitizes Neuroendocrine Tumor Cells via Peptidyl-prolyl
  cis-trans isomerase 1 Inhibition
  Xavier Keutgen, MD, The University of Chicago

Discussion

SESSION 5: CLINICAL AND THERANOSTIC STUDIES

Moderators: George Fisher, MD, Stanford University
Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center

• Digital Image Analysis in Prediction of Metastatic Midgut and Pancreatic NET Outcomes
  Stephen Ward, MD, PhD and Michelle Kim, MD, PhD, Cleveland Clinic

• Transcriptomic Influences of Racial Disparities in Pancreatic Neuroendocrine Tumors
  Brendan Herring, MS and Bart Rose, MD, University of Alabama at Birmingham School of Medicine

• A Closer Look: Fluorescent Analogs of Clinical Stage PRRT Agents Reveal Specific Binding to
  Multipotent Bone Marrow Stem Cells
  Susanne Kossatz, PhD, Technical University Munich

• Pb-203 Image-Guided Pb-212 Receptor Targeted Alpha-Particle Therapy for NETs –
  An Emerging Paradigm
  Michael Schultz, PhD, The University of Iowa

• The Wnt Pathway Protein Dvl1 Targets Sstr2 for Lysosome-dependent Degradation
  Jeffrey Frost, PhD, The University of Texas Health Science Center at Houston

• uPAR-PET in Neuroendocrine Tumor Patients: Final Results from a Prospective Phase II Trial
  and its Implications for uPAR-targeted Radionuclide Therapy
  Andreas Kjaer, PhD, University of Copenhagen

Discussion

Meeting Ends